Serial No. 10/575,977 Docket No.: X-18530

Amendments to the Claims

1-59. (cancelled)

- 60. (currently amended) An <u>purified FGFR1(IIIc)</u> antibody or <u>binding fragment Fv (fragment variable)</u> thereof <u>that binds FGFR1(IIIc)</u> comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 15 and the LCVR comprises the amino acid sequence of SEQ ID NO: 16.
- 61. (currently amended) A pharmaceutical composition comprising the antibody or antigen-binding fragment Fv (fragment variable) thereof of claim 60 and a pharmaceutically acceptable carrier.
- 62. (withdrawn) An isolated nucleic acid encoding the antibody or an antigen binding fragment thereof of claim 60.
- 63. (withdrawn) An expression vector comprising the isolated nucleic acid of claim 62.
- 64. (withdrawn) A host cell comprising the expression vector of claim 63.
- 65. (withdrawn) A method of treating obesity comprising administering to a mammal in need thereof a therapeutically effective amount of the antibody or antigen binding fragment of claim 60.
- 66. (withdrawn) A method of treating diabetes comprising administering to a mammal in need thereof a therapeutically effective amount of the antibody or antigen binding fragment of claim 60.
- 67. (withdrawn) A method of reducing food intake or a condition affected by reducing food intake comprising administering to a mammal in need thereof a therapeutically effective amount of the antibody or antigen binding fragment of claim 60.